Approach to a Patient with Elevated Serum Alkaline Phosphatase

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 199-229

  Siddique, Asma ^a   Kowdley, Kris V ^b  

^a Digestive Disease Institute   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Bile; Cholestasis; Cirrhosis; Liver

Indexed keywords

ACETYLCYSTEINE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMITRIPTYLINE; AZATHIOPRINE; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CARNITINE; CLOFIBRATE; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIGOXIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G4; METHOTREXATE; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALMEFENE; NALOXONE; NALTREXONE; PAROXETINE; PREDNISONE; RIFAMPICIN; RITUXIMAB; SERTRALINE; THIAZIDE DIURETIC AGENT; URSODEOXYCHOLIC ACID; WARFARIN;

ABNORMAL LABORATORY RESULT; ACUTE ASCENDING CHOLANGITIS; ACUTE DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE CHOLANGITIS; AUTOIMMUNE DISEASE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT DISEASE; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; CHOLESTASIS; CHRONIC DISEASE; CHRONIC NONSUPPURATIVE DESTRUCTIVE CHOLANGITIS; CLINICAL FEATURE; COMMON BILE DUCT CYST; COMMON BILE DUCT STONE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC DISORDER; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER SARCOIDOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL HISTORY; OSTEOPOROSIS; PARENTERAL NUTRITION; PARENTERAL NUTRITION HEPATOBILIARY DISEASE; PHYSICAL EXAMINATION; PLASMAPHERESIS; PREGNANCY DISORDER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTHROMBIN TIME; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SARCOIDOSIS; SCLEROSING CHOLANGITIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEX RATIO; SIDE EFFECT; TOXIC HEPATITIS; VITAMIN DEFICIENCY;

AGED; ALKALINE PHOSPHATASE; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; MALE; PARENTERAL NUTRITION; SARCOIDOSIS;

EID: 84860264787     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.012     Document Type: Review

References (205)

1. Scharschmidt B.F., Goldberg H.I., Schmid R. Current concepts in diagnosis. Approach to the patient with cholestatic jaundice. N Engl J Med 1983, 308(25):1515-1519.
2. Trauner M., Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003, 83(2):633-671.
3. Hagenbuch B., Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 2004, 447(5):566-570.
4. Niemi M., Pasanen M.K., Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011, 63(1):157-181.
5. Arrese M., Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol Med 2003, 9(12):558-564.
6. Kipp H., Arias I.M. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin Liver Dis 2000, 20(3):339-351.
7. Gerk P.M., Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002, 302(2):407-415.
8. Kullak-Ublick G.A., Beuers U., Paumgartner G. Hepatobiliary transport. J Hepatol 2000, 32(Suppl 1):3-18.
9. Lazaridis K.N., Pham L., Tietz P., et al. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest 1997, 100(11):2714-2721.
10. Xu G., Shneider B.L., Shefer S., et al. Ileal bile acid transport regulates bile acid pool, synthesis, and plasma cholesterol levels differently in cholesterol-fed rats and rabbits. J Lipid Res 2000, 41(2):298-304.
11. Rost D., Mahner S., Sugiyama Y., et al. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol Gastrointest Liver Physiol 2002, 282(4):G720-G726.
12. Wang H., Chen J., Hollister K., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999, 3(5):543-553.
13. Ananthanarayanan M., Balasubramanian N., Makishima M., et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276(31):28857-28865.
14. Cheng X., Maher J., Dieter M.Z., et al. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 2005, 33(9):1276-1282.
15. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med 1993, 117(2):187-190.
16. Schiele F., Henny J., Hitz J., et al. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 1983, 29(4):634-641.
17. Connell M.D., Dinwoodie A.J. Diagnostic use of serum alkaline phosphatase isoenzymes and 5-nucleotidase. Clin Chim Acta 1970, 30(2):235-241.
18. McIntyre N. Cholestasis. Oxford textbook of clinical hepatology 1999, 1574-1579. Oxford Medical Publications, Oxford (United Kingdom). 2th edition. J. Bircher, J.-P. Benhamou, N. McIntyre (Eds.).
19. Maggs J.R., Chapman R.W. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol 2008, 24(3):377-383.
20. Robinson J.R., Moyer C.A. Methods for differential diagnosis of painless jaundice. Surg Gynecol Obstet 1947, 85(4):535-540.
21. Center S.A. Diseases of the gallbladder and biliary tree. Vet Clin North Am Small Anim Pract 2009, 39(3):543-598.
22. Lillemoe K.D. Surgical treatment of biliary tract infections. Am Surg 2000, 66(2):138-144.
23. Bansal V., Schuchert V.D. Jaundice in the intensive care unit. Surg Clin North Am 2006, 86:1495-1502.
24. Cavestro G.M., Frulloni L., Cerati E., et al. Progressive familial intrahepatic cholestasis. Acta Biomed 2002, 73(3-4):53-56.
25. Fisher D.A., Wright T.L. Pruritus as a symptom of hepatitis C. J Am Acad Dermatol 1994, 30(4):629-632.
26. Jones E.A., Bergasa N.V. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999, 11(6):623-631.
27. Bergasa N.V. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004, 6(1):10-16.
28. Jones E.A., Bergasa N.V. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990, 11(5):884-887.
29. Milkiewicz P., Heathcote E.J. Fatigue in chronic cholestasis. Gut 2004, 53(4):475-477.
30. Talwalkar J.A., Lindor K.D. Primary biliary cirrhosis. Lancet 2003, 362(9377):53-61.
31. Walli A.K., Seidel D. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. J Clin Invest 1984, 74(3):867-879.
32. Crippin J.S., Lindor K.D., Jorgensen R., et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?. Hepatology 1992, 15(5):858-862.
33. Phillips J.R., Angulo P., Petterson T., et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96(9):2745-2750.
34. Isaia G., Di Stefano M., Roggia C., et al. Bone disorders in cholestatic liver diseases. Forum (Genova) 1998, 8(1):28-38.
35. Lui P., Ng H.S., Teh L.B., et al. Ultrasonography in the diagnosis of cholestatic jaundice. Ann Acad Med Singapore 1986, 15(2):182-185.
36. Shea J.A., Berlin J.A., Escarce J.J., et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 1994, 154(22):2573-2581.
37. Balci N.C., Befeler A.S., Leiva P., et al. Imaging of liver disease: comparison between quadruple-phase multidetector computed tomography and magnetic resonance imaging. J Gastroenterol Hepatol 2008, 23(10):1520-1527.
38. Varghese J.C., Liddell R.P., Farrell M.A., et al. Diagnostic accuracy of magnetic resonance cholangiopancreatography and ultrasound compared with direct cholangiography in the detection of choledocholithiasis. Clin Radiol 2000, 55(1):25-35.
39. NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy. NIH Consens State Sci Statements 2002, 19:1-26.
40. Berg P.A., Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992, 10:85-101.
41. Poupon R., Chazouillères O., Poupon R.E. Chronic cholestatic diseases. J Hepatol 2000, 32(Suppl 1):129-140.
42. Heathcote J. Autoimmune cholangitis. Gut 1997, 40(4):440-442.
43. Strassburg C.P., Manns M.P. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease. J Hepatol 1999, 31(4):751.
44. Charatcharoenwitthaya P., Lindor K.D. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006, 8(1):75-82.
45. Kariv R., Konikoff F.M. Sclerosing cholangitis-primary, secondary and more. Isr Med Assoc J 2002, 4(12):1141-1142.
46. Bull L.N., Carlton V.E., Stricker N.L., et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997, 26(1):155-164.
47. Strautnieks S.S., Kagalwalla A.F., Tanner M.S., et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet 1997, 61(3):630-633.
48. Jansen P.L., Müller M.M. Progressive familial intrahepatic cholestasis types 1, 2, and 3. Gut 1998, 42(6):766-767.
49. Knisely A.S., Strautnieks S.S., Meier Y., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006, 44(2):478-486.
50. Jacquemin E., De Vree J.M., Cresteil D., et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001, 120(6):1448-1458.
51. Dixon P.H., Weerasekera N., Linton K.J., et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000, 9(8):1209-1217.
52. Bull L.N., Juijn J.A., Liao M., et al. Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. Hum Genet 1999, 104(3):241-248.
53. van Mil S.W., van der Woerd W.L., van der Brugge G., et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004, 127(2):379-384.
54. Keitel V., Nies A.T., Brom M., et al. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003, 284(1):G165-G174.
55. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007, 13(6):529-536.
56. Colliton R.P., Bason L., Lu F.M., et al. Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients. Hum Mutat 2001, 17(2):151-152.
57. Jones D.E. Pathogenesis of primary biliary cirrhosis. Gut 2007, 56(11):1615-1624.
58. Jones D.E., Watt F.E., Metcalf J.V., et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999, 30(3):402-407.
59. Bloom S., Fleming K., Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 1995, 36(4):604-609.
60. Griem P., Wulferink M., Sachs B., et al. Allergic and autoimmune reactions to xenobiotics: how do they arise?. Immunol Today 1998, 19(3):133-141.
61. Varyani F.K., West J., Card T.R. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol 2011, 11:95.
62. Gershwin M.E., Selmi C., Worman H.J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42(5):1194-1202.
63. Prince M.I., Chetwynd A., Craig W.L., et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004, 53(6):865-870.
64. Newton J.L. Fatigue in primary biliary cirrhosis. Clin Liver Dis 2008, 12(2):367-383.
65. Levy C., Lindor K.D. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003, 7(4):901-910.
66. Shapiro J.M., Smith H., Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979, 20(2):137-140.
67. Leung P.S., Coppel R.L., Ansari A., et al. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:61-69.
68. Drebber U., Mueller J.J., Klein E., et al. Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage. Pathol Int 2009, 59(8):546-554.
69. Ludwig J., Dickson E.R., McDonald G.S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978, 379(2):103-112.
70. Leuschner U., Fischer H., Kurtz W., et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989, 97(5):1268-1274.
71. Poupon R.E., Lindor K.D., Parés A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003, 39(1):12-16.
72. MacQuillan G.C., Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003, 7(4):941-956.
73. Lacerda M.A., Ludwig J., Dickson E.R., et al. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995, 90(2):247-249.
74. Broome U., Olsson R., Loof L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38(4):610-615.
75. Bargen J. Complications and sequelae of chronic ulcerative colitis. Ann Intern Med 1929, 3:335-352.
76. Schrumpf E., Boberg K.M. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001, 15(4):553-562.
77. Mendes F.D., Lindor K.D. Primary sclerosing cholangitis. Clin Liver Dis 2004, 8(1):195-211.
78. Loftus E.V., Sandborn W.J., Tremaine W.J., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996, 110(5):1496-1502.
79. Bergquist A., Montgomery S.M., Bahmanyar S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008, 6(8):939-943.
80. Norris S., Kondeatis E., Collins R., et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001, 120(6):1475-1482.
81. van Milligen de Wit A.W., van Deventer S.J., Tytgat G.N. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995, 90(6):893-900.
82. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138(3):1102-1111.
83. Krasinskas A.M., Yao Y., Randhawa P., et al. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci 2007, 52(9):2265-2270.
84. Mehal W.Z., Hattersley A.T., Chapman R.W., et al. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J Hepatol 1992, 15(3):396-399.
85. Kulaksiz H., Rudolph G., Kloeters-Plachky P., et al. Biliary Candida infections in primary sclerosing cholangitis. J Hepatol 2006, 45(5):711-716.
86. Terjung B., Worman H.J. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001, 15:629-642.
87. Worthington J., Cullen S., Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005, 28:93-103.
88. Okolicsanyi L., Fabris L., Viaggi S., et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: An Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996, 8(7):685-691.
89. Olsson R., Broome U., Danielsson A., et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 1999, 46(25):136-141.
90. Ciocirlan M., Ponchon T. Diagnostic endoscopic retrograde cholangiopancreatography. Endoscopy 2004, 36(2):137-146.
91. Furmanczyk P.S., Grieco V.S., Agoff S.N. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol 2005, 124(3):355-360.
92. Angulo P., Pearce D.H., Johnson C.D., et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000, 33(4):520-527.
93. Burak K.W., Angulo P., Lindor K.D. Is there a role for liver biopsy in primary sclerosing cholangitis?. Am J Gastroenterol 2003, 98(5):1155-1158.
94. Abdalian R., Heathcote E.J. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006, 44(5):1063-1074.
95. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):523-526.
96. Charatcharoenwitthaya P., Enders F.B., Halling K.C., et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48(4):1106-1117.
97. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36(3):321-327.
98. Thackeray E.W., Charatcharoenwitthaya P., Elfaki D., et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011, 9(1):52-56.
99. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121(4):900-907.
100. Imam M.H., Sinakos E., Gossard A.A., et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011, 34(10):1185-1192.
101. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis- Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336(10):691-695.
102. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51(2):660-678.
103. Takuma K., Kamisawa T., Igarashi Y. Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opin Rheumatol 2011, 23(1):80-87.
104. Sugumar A., Chari S.T. Autoimmune pancreatitis. J Gastroenterol Hepatol 2011, 26(9):1368-1373.
105. Ghazale A., Chari S.T., Zhang L., et al. Immunoglobulin G4-Associated Cholangitis: clinical Profile and Response to Therapy. Gastroenterology 2008, 134(3):706-715.
106. Björnsson E., Chari S., Silveira M., et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011, 18(3):198-205.
107. Sahani D.V., Kalva S.P., Farrell J., et al. Autoimmune pancreatitis: imaging features. Radiology 2004, 233(2):345-352.
108. Ghazale A., Chari S.T., Smyrk T.C., et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007, 102(8):1646-1653.
109. Nakazawa T., Ohara H., Sano H., et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas 2006, 32(2):229.
110. Zen Y., Fujii T., Sato Y., et al. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 2007, 20(8):884-894.
111. Kamisawa T., Shimosegawa T., Okazaki K., et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009, 58(11):1504-1507.
112. Hirano K., Tada M., Isayama H., et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007, 56(12):1719-1724.
113. Karagiannidis A., Karavalaki M., Koulaouzidis A. Hepatic sarcoidosis. Ann Hepatol 2006, 5(4):251-256.
114. Mueller S., Boehme M.W., Hofmann W.J., et al. Extrapulmonary sarcoidosis primarily diagnosed in the liver. Scand J Gastroenterol 2000, 35(9):1003-1008.
115. Rybicki B.A., Major M., Popovich J., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997, 45(3):234-241.
116. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164:1885-1889.
117. Irani S.K., Dobbins W.O. Hepatic granulomas: review of 73 patients from one hospital and survey of the literature. J Clin Gastroenterol 1979, 1(2):131-143.
118. Cremers J., Drent M., Driessen A., et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012, 24(1):17-24.
119. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med 1975, 59(3):365-372.
120. Farman J., Ramirez G., Brunetti J., et al. Abdominal manifestations of sarcoidosis. CT appearances. Clin Imaging 1995, 19(1):30-33.
121. Kessler A., Mitchell D.G., Israel H.L., et al. Hepatic and splenic sarcoidosis: ultrasound and MR imaging. Abdom Imaging 1993, 18(2):159-163.
122. Devaney K., Goodman Z.D., Epstein M.S., et al. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993, 17(12):1272-1280.
123. Geramizadeh B., Jahangiri R., Moradi E. Causes of hepatic granuloma: a 12-year single center experience from southern Iran. Arch Iran Med 2011, 14(4):288-289.
124. Kennedy P.T., Zakaria N., Modawi S.B., et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006, 18(7):721-726.
125. Ayyala U.S., Padilla M.L. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options Gastroenterol 2006, 9(6):475-483.
126. Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000, 17(1):60-66.
127. Baratta L., Cascino A., Delfino M., et al. Ursodeoxycholic acid treatment in abdominal sarcoidosis. Dig Dis Sci 2000, 45(8):1559-1562.
128. Ebert E.C., Kierson M., Hagspiel K.D. Gastrointestinal and hepatic manifestations of sarcoidosis. Am J Gastroenterol 2008, 103(12):3184-3192.
129. Moreno-Merlo F., Wanless I.R., Shimamatsu K., et al. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology 1997, 26(3):554-560.
130. Casavilla F.A., Gordon R., Wright H.I., et al. Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med 1993, 118(11):865-866.
131. Quigley E.M., Marsh M.N., Shaffer J.L. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993, 104(1):286-301.
132. Grant J.P., Cox C.E., Kleinman L.M., et al. Serum hepatic enzyme and bilirubin elevations during parenteral nutrition. Surg Gynecol Obstet 1977, 145(4):573-580.
133. Fisher R.L. Hepatobiliary abnormalities associated with total parenteral nutrition. Gastroenterol Clin North Am 1989, 18(3):645-666.
134. Chan S., McCowen K.C., Bistrian B.R., et al. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home parenteral nutrition. Surgery 1999, 126(1):28-34.
135. Touloukian R.J., Seashore J.H. Hepatic secretory obstruction with total parenteral nutrition in the infant. J Pediatr Surg 1975, 10(3):353-360.
136. Brown M.R., Thunberg B.J., Golub L., et al. Decreased cholestasis with enteral instead of intravenous protein in the very low-birth-weight infant. J Pediatr Gastroenterol Nutr 1989, 9(1):21-27.
137. Meguid M.M., Akahoshi M.P., Jeffers S., et al. Amelioration of metabolic complications of conventional total parenteral nutrition. Arch Surg 1984, 119(11):1294-1298.
138. Beau P., Labat-Labourdette J., Ingrand P., et al. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease?. J Hepatol 1994, 20(2):240-244.
139. Capron J.P., Herve M.A., Gineston J.L., et al. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983, 1(8322):446-447.
140. Grant D. Current results of intestinal transplantation. The International Intestinal Transplant Registry. Lancet 1996, 347(9018):1801-1803.
141. Roger D., Vaillant L., Fignon A., et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol 1994, 130(6):734-739.
142. Geenes V., Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009, 15(17):2049-2066.
143. Reyes H., Radrigan M.E., Gonzalez M.C., et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology 1987, 93(3):584-590.
144. Lunzer M.R. Jaundice in pregnancy. Baillieres Clin Gastroenterol 1989, 3(2):467-483.
145. Leslie K.K., Reznikov L., Simon F.R., et al. Estrogens in intrahepatic cholestasis of pregnancy. Obstet Gynecol 2000, 95(3):372-376.
146. Pauli-Magnus C., Meier P.J., Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin Liver Dis 2010, 30(2):147-159.
147. Shaw D., Frohlich J., Wittmann B.A., et al. A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982, 142(6 Pt 1):621-625.
148. Heikkinen J. Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstet Gynecol 1983, 61(5):581-587.
149. Walker I.A., Nelson-Piercy C., Williamson C. Role of bile acid measurement in pregnancy. Ann Clin Biochem 2002, 39(Pt 2):105-113.
150. Azzaroli F., Mennone A., Feletti V., et al. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment Pharmacol Ther 2007, 26(8):1139-1146.
151. Hirvioja M.L., Tuimala R., Vuori J. The treatment of intrahepatic cholestasis of pregnancy by dexamethasone. Br J Obstet Gynaecol 1992, 99(2):109-111.
152. Moseley R.H. Sepsis and cholestasis. Clin Liver Dis 1999, 3(3):465-475.
153. Tung C.B., Tung C.F., Yang D.Y. Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. Hepatogastroenterology 2005, 52(65):1347-1350.
154. Szabo G., Romics L., Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 2002, 6(4):1045-1066.
155. Brandorg L., Goldman I. Bacterial and miscellaneous infections of the liver. Hepatology, A textbook of the liver 1990, 1086-1098. W.B. Saunders, Philadelphia. D. Zakim, T.D. Boyer (Eds.).
156. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders.'. J Hepatol 2001, 35(1):134-146.
157. Zimmerman H.J. Drug-induced liver disease. Clin Liver Dis 2000, 4(1):73-96.
158. Larrey D. Drug-induced liver diseases. J Hepatol 2000, 32(Suppl 1):77-88.
159. Geubel A.P., Sempoux C.L. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000, 15(11):1232-1238.
160. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4(6):489-499.
161. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134(6):1641-1654.
162. Yoshikado T., Takada T., Yamamoto T., et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011, 79(2):241-250.
163. Vermillion S.E., Gregg J.A., Baggenstoss A.H., et al. Jaundice associated with bacteremia. Arch Intern Med 1969, 124(5):611-618.
164. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009, 62(6):481-492.
165. Papaseit E., Farré M., López M.J., et al. A case of acute valproic acid poisoning treated successfully with L-carnitine. Eur J Emerg Med 2012, 19(1):57-58.
166. Wree A., Dechêne A., Herzer K., et al. Steroid and ursodeoxycholic acid combination in severe drug-induced liver injury. Digestion 2011, 84(1):54-59.
167. Kratzer W., Mason R.A., K'achele V. Prevalence of gallstones in sonographic surveys worldwide. J Clin Ultrasound 1999, 27(1):1-7.
168. Lee J.G. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol 2009, 6(9):533-541.
169. Rosseland A.R., Glomsaker T.B. Asymptomatic common bile duct stones. Eur J Gastroenterol Hepatol 2000, 12(11):1171-1173.
170. Wada K., Takada T., Kawarada Y., et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg 2007, 14(1):52-58.
171. Sahu M.K., Chacko A., Dutta A.K., et al. Microbial profile and antibiotic sensitivity pattern in acute bacterial cholangitis. Indian J Gastroenterol 2011, 30(5):204-208.
172. Lindsell D.R. The diagnostic accuracy of magnetic resonance cholangiopancreatography (MRCP) and ultrasound compared with direct cholangiography in the detection of choledocholithiasis. Clin Radiol 2000, 55(7):579.
173. Sugiyama M., Atomi Y. Endoscopic ultrasonography for diagnosing choledocholithiasis: a prospective comparative study with ultrasonography and computed tomography. Gastrointest Endosc 1997, 45(3):143-146.
174. Gigot J., Nagorney D., Farnell M., et al. Bile duct cysts: a changing spectrum of disease. J Hepatobiliary Pancreat Surg 1996, 3:405-411.
175. Yu Z.L., Zhang L.J., Fu J.Z., et al. Anomalous pancreaticobiliary junction: image analysis and treatment principles. Hepatobiliary Pancreat Dis Int 2004, 3(1):136-139.
176. Shah O.J., Shera A.H., Zargar S.A., et al. Choledochal cysts in children and adults with contrasting profiles: 11-year experience at a tertiary care center in Kashmir. World J Surg 2009, 33(11):2403-2411.
177. Huang C.T., Lee H.C., Chen W.T., et al. Usefulness of magnetic resonance cholangiopancreatography in pancreatobiliary abnormalities in pediatric patients. Pediatr Neonatol 2011, 52(6):332-336.
178. Dinsmore J.E., Murphy J.J., Jamieson D. Pediatric surgical images: MRCP evaluation of choledochal cysts. J Pediatr Surg 2001, 36(5):829-830.
179. de Vries J.S., de Vries S., Aronson D.C., et al. Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg 2002, 37:1568-1573.
180. Edil B.H., Cameron J.L., Reddy S., et al. Type III is intraduodenal (choledochocele). Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg 2008, 206(5):1000-1005. [discussion: 1005-8].
181. Richardson M.C., Bell G., Fullarton G.M., et al. Incidence and nature of bile duct injuries following laparoscopic cholecystectomy: an audit of 5913 cases. West of Scotland Laparoscopic Cholecystectomy Audit Group. Br J Surg 1996, 83(10):1356-1360.
182. Sharma S., Gurakar A., Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl 2008, 14(6):759-769.
183. Rohrman C.A., Baron R.L. Biliary complications of pancreatitis. Radiol Clin North Am 1989, 27(1):93-104.
184. Deviere J., Cremer M., Baize M., et al. Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents. Gut 1994, 35(1):122-126.
185. Dixon J.M., Armstrong C.P., Duffy S.W., et al. Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut 1983, 24(9):845-852.
186. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95(1):204-207.
187. Kipp B.R., Stadheim L.M., Halling S.A., et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004, 99(9):1675-1681.
188. Datta D.V., Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963, 1(5325):216-219.
189. Carey J.B., Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961, 176:432-435.
190. Podesta A., Lopez P., Terg R., et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991, 36(2):216-220.
191. Tandon P., Rowe B.H., Vandermeer B., et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007, 102(7):1528-1536.
192. Bloomer J.R., Boyer J.L. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975, 82(3):310-317.
193. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45(3):666-674.
194. Zylicz Z., Krajnik M., Sorge A.A., et al. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003, 26(6):1105-1112.
195. Bergasa N.V., Talbot T.L., Alling D.W., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992, 102(2):544-549.
196. Jones E.A., Neuberger J., Bergasa N.V. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002, 95(8):547-552.
197. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian multicenter double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19(5):1149-1156.
198. Gross C.R., Malinchoc M., Kim W.R., et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999, 29(2):356-364.
199. Vuoristo M., Farkilla M., Kamonen A.L., et al. A placebo controlled trial of primary biliary cirrhosis with colchicines and ursodeoxycholic acid. Gastroenterology 1995, 108(5):1470-1478.
200. Jones D.E., Newton J.L. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007, 25(4):471-476.
201. Guanabens N., Pares A., Ros I., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003, 98(10):2268-2274.
202. Balan V., Dickson E.R., Jorgensen R.A., et al. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc 1994, 69(10):923-929.
203. Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969, 57(3):253-256.
204. Stojakovic T., Putz-Bankuti C., Fauler G., et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007, 46(3):776-784.
205. Cohen L.B., Ambinder E.P., Wolke A.M., et al. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985, 26(3):291-294.